Antonio M Lantin, MD | |
7980 S Crescent Blvd, Delaware Valley Medical, Pennsauken, NJ 08109-4106 | |
(856) 665-5100 | |
(856) 665-5212 |
Full Name | Antonio M Lantin |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 7980 S Crescent Blvd, Pennsauken, New Jersey |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1184871766 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 25MA03862900 (New Jersey) | Primary |
208D00000X | General Practice | D06069300 (New Jersey) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Antonio M Lantin, MD 7980 S Crescent Blvd, Delaware Valley Medical, Pennsauken, NJ 08109-4106 Ph: (856) 665-5100 | Antonio M Lantin, MD 7980 S Crescent Blvd, Delaware Valley Medical, Pennsauken, NJ 08109-4106 Ph: (856) 665-5100 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.
Researchers at Cardiff University have found that online information about ovarian cancer can cause as much worry as comfort for women at high risk of developing the disease, in a new study published in ecancer.
Research conducted at LSU Health New Orleans Neuroscience Center of Excellence reports that a combination of an LSU Health-patented drug and selected DHA derivatives is more effective in protecting brain cells and increasing recovery after stroke than a single drug. The findings are published in Brain Circulation, available here.
The July edition of SLAS Discovery is a Special Edition featuring the cover article, "Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry" by Lesley-Anne Pearson, Charlotte J. Green, Ph.D., De Lin, Ph.D., Alain-Pierre Petit, Ph.D., David W. Gray, Ph.D., Victoria H. Cowling, Ph.D., and Euan A. F. Fordyce, Ph.D., (Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, UK).
› Verified 2 days ago